Steven Sangha Announces Voting and Support Agreement for Sernova Biotherapeutics Inc.'s Proposed Business Combination with Seraxis Holdings, Inc.
Sernova and Seraxis Enter Definitive Merger Agreement to Create a Differentiated Type 1 Diabetes Islet Cell-Replacement Biotech Company, BetaNova Biotherapeutics
Sernova Biotherapeutics Receives FDA Orphan Drug Designation for Autologous Islet Transplantation for Prevention of Diabetes Due to Total Pancreatectomy
Sernova Biotherapeutics Announces Affirmative Voting Results from 2026 Annual General Meeting of Shareholders
Sernova Biotherapeutics Strengthens Balance Sheet with $7.1 Million in Financings Plus Net Retirement of a Cumulative $17 Million of Debt Subject to Shareholder Approval
Sernova Biotherapeutics Closes First Tranche of a Private Placement of Equity Financing to Support Ongoing Clinical Efforts
Sernova Biotherapeutics Announces $13 Million Debt-to-Equity Conversion Eliminating Significant Financing Overhang
Sernova Biotherapeutics Appoints John L. Brooks III, Former Chair and CEO of Joslin Diabetes Research Center, as Chair of the Board of Directors
SAGA Metals Reports 8 Completed Drill Holes at Trapper North Aimed to Expand the MRE at the Radar Critical Minerals Project
SAGA Metals Reports 8 Completed Drill Holes at Trapper North Aimed to Expand the MRE at the Radar Critical Minerals Project
SAGA Metals Reports 8 Completed Drill Holes at Trapper North Aimed to Expand the MRE at the Radar Critical Minerals Project
Steadright Begins Exploration at Péribonka Ree-Niobium Carbonatite Target in Quebec's Niobium District
Red Metal Reports Mine Sampling at Farellon, Including 6.8% Copper on Level 7 and 6.05% Copper on Level 9
